Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).

被引：0
|
作者：
Ruff, P [1 ]
Moodley, SD [1 ]
Rapoport, BL [1 ]
Chasen, MR [1 ]
Jacobs, C [1 ]
Hacking, D [1 ]
Voroblof, DA [1 ]
机构：
[1] S African Caelyx Investigators Grp, Johannesburg, South Africa
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306P
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [21] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
  • [22] Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck
    Harrington, KJ
    Lewanski, C
    Northcote, AD
    Whittaker, J
    Peters, AM
    Vile, RG
    Stewart, JSW
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) : 2015 - 2022
  • [23] Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma
    Dvorák, J
    Zoul, Z
    Melichar, B
    Jandík, P
    Mergancová, J
    Motycková, I
    Kalousová, D
    Petera, J
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 34 (01) : 96 - 98
  • [24] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [25] Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer
    Nicoletto, MO
    Falci, C
    Pianalto, D
    Artioli, G
    Azzoni, P
    De Masi, G
    Ferrazzi, E
    Perin, A
    Donach, M
    Zoli, W
    GYNECOLOGIC ONCOLOGY, 2006, 100 (02) : 318 - 323
  • [26] Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
    Jalid Sehouli
    O. Camara
    M. Schmidt
    S. Mahner
    G. Seipelt
    B. Otremba
    B. Schmalfeldt
    H. Tesch
    C. Lorenz-Schlüter
    G. Oskay-Özcelik
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 585 - 591
  • [27] Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer:: a phase II study by the Hellenic Cooperative Oncology Group
    Gogas, H
    Papadimitriou, C
    Kalofonos, HP
    Bafaloukos, D
    Fountzilas, G
    Tsavdaridis, D
    Anagnostopoulos, A
    Onyenadum, A
    Papakostas, P
    Economopoulos, T
    Christodoulou, C
    Kosmidis, P
    Markopoulos, C
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1737 - 1742
  • [28] Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
    Rom, Joachim
    Bechstein, Sarah
    Domschke, Christoph
    Golatta, Michael
    Mayer, Christine
    Heil, Joerg
    Thum, Janina
    Smetanay, Katharina
    Windemuth-Kieselbach, Christine
    Wallwiener, Markus
    Marme, Frederik
    Schuetz, Florian
    Sohn, Christof
    Schneeweiss, Andreas
    ANTI-CANCER DRUGS, 2014, 25 (02) : 219 - 224
  • [29] Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study
    Hong, RL
    Tseng, YL
    Chang, FH
    ANNALS OF ONCOLOGY, 2000, 11 (03) : 349 - 353
  • [30] Phase II pilot study of Caelyx (doxorubicin HCI, pegylated liposomal) in patients with inoperable squamous cell cancer of the head and neck
    Harrington, KJ
    Harrison, D
    Stewart, JSW
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S33 - S33
12345